CompletedPhase 2NCT00433381
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Mark GilbertRadiation Therapy Oncology Group
- Intervention
- Bevacizumab(biological)
- Enrollment
- 123 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2011
Study locations (30)
- Mobile Infirmary Medical Center, Mobile, Alabama, United States
- Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
- Arizona Oncology Services Foundation, Scottsdale, Arizona, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Mills-Peninsula Medical Center, Burlingame, California, United States
- John Muir Medical Center-Concord Campus, Concord, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Marin General Hospital, Greenbrae, California, United States
- Sutter Cancer Research Consortium, Novato, California, United States
- California Pacific Medical Center-Pacific Campus, San Francisco, California, United States
- Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States
- John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States
- Yale University, New Haven, Connecticut, United States
- Boca Raton Regional Hospital, Boca Raton, Florida, United States
- University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
American College of Radiology Imaging Network · Radiation Therapy Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00433381 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05363826Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®Photolitec LLC